News


All News

Researchers in India report they have developed a radiation spot treatment for basal cell carcinoma (BCC) that destroys facial tumors without surgery or major radiation therapy in 80 percent of patients in a small study.

Sun Exposure : Despite increased warnings, people continue to tan at an alarming rate. Why aren’t they receiving the message? Lessons in Lyme disease : Researchers plan clinical trial to investigate treatment for post-infection chronic inflammation Clinical Dermatology : Newly approved microwave device zaps hyperhidrosis Cosmetic Dermatology : Tips and tricks to manage hair growth Cutaneous Oncology : SLNB is appropriate for some thin melanomas Practice Management : Stop embezzlement in your practice before it starts Special Report : Psychodermatology

The medical world is changing; this is fact. Exactly how these changes will translate into practice and affect dermatology is unclear. So unclear, in fact, that many are scrambling to address issues that may or may not be relevant as the model for healthcare delivery is debated on national, state and local levels. This leaves dermatology at the apex of a trisection between science, art and policy that warrants further inquiry.

Healthcare issues are heating up. Take, for example, recovery audit contractors (RACs), Z-Picks (bounty hunters for the commercial carriers), Obamacare being challenged in the U.S. Supreme Court, the Office of Inspector General (OIG) "hit list" targeting providers for overpayments, fraud and abuse allegations, and 5010 playing havoc with our claims processing system. What else can go wrong?

"A new microwave-based device is achieving long-lasting results in treating hyperhidrosis, said Suzanne L. Kilmer, M.D., at this year's MauiDerm: Advances in Cosmetic and Medical Dermatology. Approved for primary axillary hyperhidrosis in January 2011, the miraDry System (Miramar Labs) essentially kills targeted sweat glands with microwave energy."

Interferon and the recently Food and Drug Administration-approved pegylated interferon remain relevant adjuvant therapies for patients with lymph node-positive melanoma, even in light of advances with CTLA4 blockade and BRAF-targeted therapies for late-stage disease, says Vernon K. Sondak, M.D., chairman, department of cutaneous oncology, Moffitt Cancer Center, Tampa, Fla.

Differentiating benign nail pigmentations such as melanonychia from either nail or nail matrix melanoma is especially difficult in children because pediatric lesions present differently than they do in adults, according to Antonella Tosti, M.D., professor of the department of dermatology and cutaneous surgery, University of Miami Miller School of Medicine.

Motivation, opportunity and rationalization. This may sound like the title of a new James Bond film, but in reality, it's the triad of factors that provides fertile ground for the internal fraud that is an all-too-common occurrence in dermatologists' offices. A recent survey by the Medical Group Management Association (MGMA) revealed that 82.8 percent of managers had worked in a practice that experienced embezzlement.

Dermatology Times welcomes Albert C. Yan, M.D., as the newest member to its Editorial Advisory Council. Dr. Yan is the chief of pediatric dermatology at Children's Hospital of Philadelphia, where he is also an associate professor of pediatrics and dermatology at the Perelman School of Medicine at the University of Pennsylvania.

The combined use of propranolol and pulsed dye laser (PDL) resulted in more rapid and complete clearance of infantile hemangiomas than propranolol monotherapy, according to data presented at the 2012 annual meeting of the American Society for Laser Medicine and Surgery.

Sentinel lymph node (SLN) status represents the most important prognostic factor for disease-specific survival in primary cutaneous melanomas, said Christopher K. Bichakjian, M.D., at the 70th annual meeting of the American Academy of Dermatology. However, he says, its impact on overall survival remains unclear.

According to the National Cancer Institute, skin cancer is the most common cancer in the United States, and its prevalence keeps growing. And despite an abundance of initiatives designed to increase sun protection and early detection, people don't seem to be acting on what they know.

The estate of a deceased patient has sued Dr. Mole for not making a melanoma diagnosis earlier. The plaintiff's attorney has offered a settlement agreement for $1 million. He is concerned about the settlement being listed in the National Data Practitioner Data Bank. His attorney assures Dr. Mole that as this late point in his career this will do little to no impact on his reputation.